Immunotherapy and targeted therapies in advanced castration resistant prostate cancer

Abstract

Prostate Cancer (PC) is the second most frequent type of cancer in men worldwide. The therapeutic strategy for advanced PC continues to be based on androgen deprivation therapy usually in combination with chemotherapy or androgen receptor-targeting therapy. However, new therapies such as targeted therapies or immune-based therapy have emerged as an option for the treatment of this disease. Immunotherapy approaches have been encouraged since the approval of sipuleucel-T by the FDA in 2010. In addition, these new agents have stimulated the search for predictors of response and resistance and have improved the understanding of the biological mechanisms how they. This chapter discusses the rationale for using immunotherapy in PC and the recent clinical developments of immune-based therapies for this disease. Alongside reviewing the approved immune-based therapies, we present an overview of the experimental promising agents, such as PROSTVAC-VF Tricom vaccine or new approaches using the checkpoints inhibitors.